Biểu đồ giá cổ phiếu OTLK
OTLK Dự đoán giá cổ phiếu
Outlook Therapeutics Inc
$0.26
-8.03%
$-0.02
Khi đóng cửa: Apr 28, 16:00:00 GMT-4
$0.27
3.01%
$0
Phiên trước giờ: Apr 29, 05:12:14 GMT-4
Quay lại
Outlook Therapeutics Inc (OTLK) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$0.285
Giá mở cửa
$0.285
Phạm vi ngày
$0.2566 - $0.2874
Phạm vi 52 tuần
$0.161 - $3.39
Khối lượng
4.9M
Khối lượng trung bình
2.6M
Tỷ suất cổ tức
--
EPS (TTM)
-2.71
Vốn hóa thị trường
$22.4M
OTLK là gì?
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 17 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
